Algernon Pharmaceuticals Appoints Leading Liver Disease Expert Dr. Arun Sanyal to Its Medical and Scientific Advisory Board
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Dr. Arun Sanyal, a leading global expert and clinician in the area of chronic liver disease, has joined the Algernon Medical and Scientific Advisory Board.
Arun Sanyal, MD, has developed, mediated and encouraged global liver research as a physician-scientist for 25 years. Currently, Dr. Sanyal is the Vlahcevic Chair of Medicine in the department of Internal Medicine at Virginia Commonwealth University (VCU) and Director of the KL2 program in the Center for Clinical and Translational Research at VCU.
His esteemed medical career has spanned the spectrum of translational science in liver cirrhosis, NASH and non-alcoholic fatty liver disease (NAFLD), with a particular focus on obesity and cardiovascular affects related to liver disease. Dr. Sanyal is a past President of the AASLD (American Association for the Study of Liver Diseases), and has chaired committees at the NIDDK NASH clinical research network and the NIH hepatobiliary study section. He recently received the 2018 Distinguished Achievement Award from the American Association for the Study of Liver Diseases. The award signifies 30 years of research including 17 continuous years of National Institutes of Health funding, the development of therapeutics reducing liver disease across the globe, and countless international leadership roles and awards.
Dr. Sanyal continues to lead a number of major drug trials for the treatment of NASH with the support of his research nurses, fellow post-doctoral staff-members and laboratory professionals. Dr. Sanyal has published numerous liver disease papers in leading medical journals and periodicals throughout his career.
“I am very pleased that Dr. Sanyal accepted our invitation to join the Algernon Advisory Board,” said Christopher J, Moreau, CEO of Algernon pharmaceuticals. “He has made significant contributions as a global thought leader in the area of chronic liver disease and we look forward to both his medical and scientific guidance and direction as we advance towards our first human clinical trials.”
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Released March 21, 2019
